Boulder, Colorado - January 2, 2007 - Bolder BioTechnology, Inc. is pleased to announce that it has been granted patents 7,148,333 and 7,153,943 by the United States Patent and Trademark Office. Joe Cox, Company President said "These patents provide important intellectual property protection for our long-acting granulocyte-macrophage colony-stimulating factor (GM-CSF) analogs. GM-CSF is a human protein that stimulates bone marrow cells to divide and differentiate into mature white blood cells, which play a central role in the body's ability to fight infections. Recombinant GM-CSF products are used to treat neutropenia (low numbers of white blood cells) and reduce the incidence of severe infections in cancer patients receiving chemotherapy, to accelerate bone marrow recovery in cancer patients receiving bone marrow transplants and to increase numbers of peripheral blood progenitor cells for transplantation. A limitation of currently marketed GM-CSF products is the need to administer the proteins by daily injection, which represents a significant inconvenience for patients. Our long-acting GM-CSF analogs are designed to be more patient-friendly, with an anticipated dosing frequency of only once every one to two weeks. In preclinical animal studies our long-acting GM-CSF analogs stimulated greater and longer-lasting increases in white blood cells than standard GM-CSF proteins and were effective in disease models in which standard GM-CSF proteins were not effective. These data suggest that our long-acting GM-CSF analogs may prove more effective than currently marketed GM-CSF proteins for treating human diseases."
Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create proprietary, long-acting human protein pharmaceuticals for the treatment of hematopoietic and endocrine disorders, cancer and infectious diseases. Research leading to the development of the Company's long acting GM-CSF analogs has been supported by two Small Business Innovation Research (SBIR) grants awarded to Bolder BioTechnology by the National Cancer Institute of the National Institutes of Health. For additional information about Bolder BioTechnology, Inc., please visit our web site at www.bolderbio.com.
Statements contained herein that are not historical facts are forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company. These factors include, but are not limited to: (1) the Company's ability to successfully complete product research and development, including pre-clinical and clinical studies, and commercialization; (2) the Company's ability to obtain required government approvals; (3) the Company's ability to attract and/or maintain manufacturing, sales, distribution and marketing partners; and (4) the Company's ability to develop and commercialize its products before its competitors.
Contact information: Joe Cox, Ph.D., President (303) 420-4420 ext.202
